证券代码：002873 证券简称：新天药业 公告编号：2025-062 股东 名称 是否控股 股东及一 致行动人 本次质押 数量（股） 占其所 持股份 比例 占公司 总股本 比例 是否为 限售股 是否 为补 充质 押 质押 起始 日 质押 到期 日 质权人 质押 用途 新天 智药 是 5,210,000 7.38% 2.13% 否 否 2025. 12.19 2026. 6.18 浙商证 券股份 有限公 司 置换 存量 质押 融资 一、股份质押的基本情况 截至本公告日，新天智药所持质押股份情况如下： 股东 名称 持股数量 （股） 持股 比例 本次质 押前累 计质押 股份数 量（股） 本次质 押后累 计质押 股份数 量（股） 占其 所持 股份 比例 占公 司总 股本 比例 已质押股份情况 未质押股份情况 已质押股 份限售和 冻结数量 （股） 占已 质押 股份 比例 未质押股 份限售和 冻结数量 （股） 占未 质押 股份 比例 新天 智药 70,589,266 28.92 % 48,036, 844 53,246, 844 75.43 % 21.81 % 0 0% 0 0% 注：上表中新天智药质押率较前期上升系其 ...

Group 1 - A total of 78 stocks in the A-share market experienced block trading today, with a total transaction value of 3.755 billion yuan [1] - The top three stocks by transaction value were Minsheng Bank (2.149 billion yuan), WuXi AppTec (430 million yuan), and Luxin Technology (119 million yuan) [1] - Among the stocks, 8 were traded at par, 3 at a premium, and 67 at a discount; the highest premium rates were for AVIC Optoelectronics (8.04%), Zhongke Shuguang (7.92%), and Haowei Group (2.07%) [1] Group 2 - The top buying amounts from institutional special seats were led by WuXi AppTec (251 million yuan) and Minsheng Bank (108 million yuan) [2] - The top selling amounts from institutional special seats included Jintian Titanium Industry (18.74 million yuan) and Huilong New Materials (9.97 million yuan) [2]

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-12-18 | 002873 | 新天药业 | 8.78 | 22.78 | | 200.01 机构专用 | 华创证券有限责任 | | | | | | | | | 公司深圳香梅路证 | | | | | | | | | 券营业部 | | 2025-12-18 | 002873 | 新天药业 | 8.78 | 22.78 | | 200.01 机构专用 | 华创证券有限责任 | | | | | | | | | 公司深圳香梅路证 | | | | | | | | | 券营业部 | | 2025-12-18 | 002873 | 新天药业 | 8.78 | 22.78 | | 200.01 机构专用 | 华创证券有限责任 | | | | | | | | | 公司深圳香梅路证 | | | | | | | | | 券营业部 | ...

Core Viewpoint - The company is advancing its innovative drug development as planned, with a focus on a new treatment for cancer-related fatigue [1] Group 1: Drug Development Progress - The company has received approval from the drug regulatory authority for clinical trials of its Xinlikang capsules, aimed at treating cancer-related fatigue, which is a significant milestone in its research efforts [1]

Group 1 - The company is currently advancing its innovative drug development as planned [2] - The Xinlikang capsule, used for treating cancer-related fatigue, received approval for clinical trials from the drug regulatory authority in October 2025 [2]

Group 1 - The core point of the article is that Xintian Pharmaceutical (002873) reported a total of 29,863 shareholders as of December 10, 2025 [1]

| 权益类证券大宗交易(协议交易) | | | | | | | 回 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-12-15 | 002873 | 新天药业 | 8.96 | 23.00 | 206.08 机构专用 | | 国泰海通证券股份 | | | | | | | | | 有限公司上海普陀 | | | | | | | | | 区铜川路证券营业 | | | | | | | | | 司 | 12月15日，新天药业大宗交易成交23万股，成交额206.08万元，占当日总成交额的4.68%，成交价8.96 元，较市场收盘价9.95元折价9.95%。 ...

证券日报网讯12月3日，新天药业（002873）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东人数为30263户。 ...

Group 1 - The core point of the news is that Xintian Pharmaceutical conducted a block trade on December 3, with a total of 210,000 shares traded at a price of 9.58 yuan, which is a discount of 10.05% compared to the market closing price of 10.65 yuan [1][2]. Group 2 - The block trade accounted for 3.91% of the total trading volume on that day, with a total transaction value of 2.0118 million yuan [1][2].